- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Lorad adapts DSM to upright mammography
Mammography vendor Loradhas made advances in retrofitting its digital breast biopsy technologyto the StereoLoc upright needle biopsy system, according to presidentHal Kirshner. Lorad, of Danbury, CT, will display a version ofits DSM (digital spot
Mammography vendor Loradhas made advances in retrofitting its digital breast biopsy technologyto the StereoLoc upright needle biopsy system, according to presidentHal Kirshner. Lorad, of Danbury, CT, will display a version ofits DSM (digital spot mammography) device that has been adaptedto work with the StereoLoc biopsy guide on the M-III mammographyunit.
The adaptation will enable Lorad users to conduct digitallyguided needle biopsies with patients in the upright position.Using the DSM/StereoLoc/M-III combination will give mammographersmore flexibility in conducting breast biopsy procedures, Kirshnersaid. The combination also gives mammographers the advantage ofusing the motor-driven DSM system.
Lorad will also display the latest work on its full-breastdigital mammography system. The company will once again show awork-in-progress prototype in its exhibit booth, and will displayboth hard- and soft-copy images acquired with the system thatshow its penetration of dense breast tissue.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
